- Risk Factors for discontinuation of etonogestrel subdermal implants in users.
| Factors | Discontinuation | P-values* | OR (95% CI)** |
|---|---|---|---|
| Age (years) | |||
| <40 | 9/35 (26.0) | <0.6 | |
| ≥40 | 65/297 (22.0) | ||
| Body mass index (kg/m2) | |||
| <30 | 46/203 (23.0) | <0.88 | |
| ≥30 | 25/106 (25.0) | ||
| Counseling | |||
| Yes | 53/266 (20.0) | <0.02 | 0.48 (0.25-0.94) |
| No | 19/54 (35.0) | ||
| Arm pain or numbness | |||
| Yes | 24/64 (32.0) | <0.002 | 2.5 (1.35-4.7) |
| No | 50/268 (19.0) | ||
| Mood changes | |||
| Yes | 25/101 (25.0) | <0.56 | |
| No | 49/229 (21.0) | ||
| Menstrual abnormalities | |||
| Yes | 63//294 (21.0) | <0.4 | 0.694 (0.3-1.59) |
| No | 10/35 (29.0) | ||
| Headache | |||
| Yes | 17/59 (29.0) | <0.164 | |
| No | 54/267 (20.0) | ||